ELC Group Signs 1.5 Million Euro Regulatory Affairs Contract
News May 01, 2015
ELC Group has announced that it has been awarded a 1.5 million Euro contract by one of China’s biggest pharmaceutical companies.
The contract award is a major endorsement of ELC Group’s new Concept to Commercialization solution approach, which delivers a highly integrated portfolio of regulatory affairs consultancy services to customers, from the development stage through to the implementation of clinical trials, completion of product registration, and successful marketing of the product.
The major project, which will see two products taken through ELC Group’s end-to-end Concept to Commercialization service, is expected to be complete by the end of 2016. The customer, one of the top 25 Chinese pharmaceutical companies, is an active pharmaceutical ingredient company that is moving towards the finished formulation business.
ELC Group was successfully selected for the contract following a rigorous qualification process, which compared ELC Group against a number of other domestic and international Clinical Research Organizations (CROs). The key measurement criteria included experience, quality of work, timeline, costing and working culture.
The client was impressed by ELC Group’s comprehensive Concept to Commercialization model and confident that ELC Group could be relied on to support their crucial international market expansion plan. Additionally, open communication, common language and cultural understanding were key factors that helped ELC to stand out in the tendering process as the ultimate partner.
Commenting on the landmark deal, ELC Group CEO Marco Rubinstein said: “Breaking boundaries is becoming a norm for ELC Group, and this landmark contract award marks an exciting new level for us, both in size and scope of projects.” He added: “This latest deal really validates our Concept to Commercialization partnership approach and its strengths in delivering end-to-end support to customers targeting ambitious growth.”
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Medherant Expands Team with Appointment of David Davies as Head of DevelopmentNews
Medherant Ltd, a leader in next-generation transdermal drug delivery, is pleased to announce the appointment of a new senior executive, David Davies, as Head of Development.READ MORE
Empowering Women in Technology Key to Boosting UK EconomyNews
A new report launched at London Stock Exchange for International Women’s Day, reveals the critical role women play in driving economic growth across the UK, with detailed research on 1,279 women-led companies showing a total contribution of £25.9 billion in revenue to the UK economy.READ MORE
Comments | 0 ADD COMMENT
World Congress on Clinical And Medical Microbiology
Sep 10 - Sep 11, 2018